NeuroSense Therapeutics remains a clinical-stage biopharmaceutical entity focused on neurodegenerative disorders, with its lead candidate PrimeC advancing amid significant financial headwinds. Despite increasing R&D investment supporting clinical milestones, the company reported a deepening net loss of $11.125 million and suffers from a strained liquidity position evidenced by a current ratio of 0.31 as of year-end 2025. Funding operations currently relies heavily on shareholder financing, setting a clear need for additional capital to sustain drug development programs. Near-term value inflection hinges on PrimeC's regulatory progress balanced against ongoing capital challenges.